PDCD1 and neutropenia: Diagnosis with hematological malignancy was found to significantly increase the odds of having hematological complications (either neutropenia or thrombocytopenia) when patients are treated with anti-PD1 or anti-PD-L1 compared to solid malignancies [OR = 17.18; 95% CI 4.06–72.71].